中药通过调节雄激素受体信号通路治疗前列腺癌的研究进展  

Progress in search for traditional Chinese medicine treating prostate cancer via androgen receptor signaling regulation

作　　者：曹爱娇 邵瑞[1,2] 王彧[1,2] 

机构地区：[1]天津中医药大学天津市现代中药重点实验室,天津300193 [2]天津国际生物医药联合研究院中药新药研发中心,天津300457

出　　处：《中国临床药理学杂志》2017年第13期1263-1266,共4页The Chinese Journal of Clinical Pharmacology

基　　金：天津市应用基础与前沿技术研究计划基金资助项目(14JCYBJC42900)

摘　　要：前列腺癌是男性生殖系统最为常见的恶性肿瘤,雄激素及其受体可能作为起始因子,驱动前列腺癌的发生。越来越多的报道表明,中药在前列腺癌的防治中具有明显优势。本文主要概述雄激素受体(AR)与前列腺癌发生发展的关系,并分别介绍了通过干预AR通路治疗前列腺癌的中药复方、单方和单体及其作用机制。Prostate cancer is the most common malignant tumor in male reproductive system, and androgen receptor（ AR） signaling plays a critical role in the development and progression of prostate cancer.Traditional Chinese medicine shed light on the prevention and treatment of prostate cancer. Here,we focus on the relationship between AR and prostate cancer, as well as the mechanisms of traditional Chinese medicine compound,unilateral and monomer,which inhibits prostate cancer progression by regulating AR signaling.

关 键 词：前列腺癌 雄激素 雄激素受体 抗前列腺癌中药 

分 类 号：R28[医药卫生—中药学]